Amid a share value slump and executive turmoil, Pfizer reported a robust quarter, thanks in part to Covid-19 drug sales.

With a market cap of $161.3 billion, New York-based Pfizer Inc. (PFE) is a leading global biopharmaceutical company. Known ...

Pfizer, Sanofi and others report Q3 beats; AbbVie, Roche and Novartis strike big deals; the 2024 presidential election looms; ...

Pfizer Inc. Chief Executive Officer Albert Bourla said he’ll do “whatever it takes” to keep profits growing, including ...

Pfizer's quarterly earnings handily beat expectations, a boost for the company as it faces pressure from an activist investor ...

Pfizer chief executive Albert Bourla hit back at Starboard Value in its third-quarter results call, criticising the activist ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the latest C ...

Pfizer punched back against activist investor Starboard Value on Tuesday, delivering positive quarterly results.

Pfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, ...

Tuesday was a fairly eventful news day for U.S. pharmaceutical sector company Pfizer (NYSE: PFE). It reported third-quarter ...

Pfizer had a "constructive" meeting with activist investor Starboard Value last week and spoke publicly about it for the ...

Pfizer reported an earnings beat Tuesday morning and raised its full-year outlook, seeing strength in sales of its Covid ...